{"id":392321,"date":"2020-12-03T02:03:51","date_gmt":"2020-12-03T07:03:51","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=392321"},"modified":"2020-12-03T02:03:51","modified_gmt":"2020-12-03T07:03:51","slug":"jazz-pharmaceuticals-and-pharmamar-announce-results-of-atlantis-phase-3-study-evaluating-zepzelca-in-combination-with-doxorubicin-for-patients-with-small-cell-lung-cancer-following-one-prior","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-and-pharmamar-announce-results-of-atlantis-phase-3-study-evaluating-zepzelca-in-combination-with-doxorubicin-for-patients-with-small-cell-lung-cancer-following-one-prior\/","title":{"rendered":"Jazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca\u2122 in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platinum-containing Line"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n DUBLIN<\/span>, Dec. 3, 2020<\/span> \/PRNewswire\/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ), along with its partner, PharmaMar (MSE: PHM), today announce results from the ATLANTIS Phase 3 multicenter, randomized, controlled study evaluating Zepzelca\u2122 (lurbinectedin) in combination with doxorubicin versus physician’s choice of topotecan or cyclophosphamide\/doxorubicin\/vincristine (CAV) for adult patients with small cell lung cancer (SCLC) whose disease progressed following one prior platinum-containing line. Patients received lurbinectedin at 2.0mg\/m2<\/sup> in the combination arm, which is lower than the FDA approved dose of Zepzelca<\/i> at 3.2mg\/m2<\/sup>.<\/p>\n

The study did not meet the pre-specified criteria of significance for the primary endpoint of overall survival (OS) in the intent-to-treat (ITT) population comparing lurbinectedin in combination with doxorubicin to the control arm, though there was no adverse effect on OS with the experimental arm. Based on the study design, no additional hypotheses were formally tested. Importantly, key secondary and subgroup analyses favored the lurbinectedin combination arm. Lurbinectedin monotherapy was not tested in ATLANTIS.<\/p>\n

The safety data in this study was consistent with the known safety profile of lurbinectedin monotherapy with no new safety signals observed. The experimental arm showed favorable safety and tolerability with regard to Grade-3 or greater drug related adverse events (AEs), deaths due to AEs, hematologic toxicity, dose reductions and treatment discontinuations due to AEs, compared to the control arm. <\/p>\n

“Bringing Zepzelca<\/i> to the U.S. market earlier this year alongside our partner, PharmaMar, was an important advance for adults with metastatic SCLC, an aggressive disease with a historically poor prognosis,” said Robert Iannone M.D<\/span>., M.S.C.E., executive vice president, research and development of\u00a0Jazz Pharmaceuticals. “While the combination of lurbinectedin and doxorubicin did not achieve the primary endpoint in this study, the overall results support the activity and tolerability of lurbinectedin in this line of therapy. We look forward to the further development of lurbinectedin in SCLC and other tumors, both as monotherapy and in combination.” <\/p>\n

“We remain committed to improving outcomes for patients with metastatic small cell lung cancer where there is a high unmet medical need; we continue to evaluate the safety and efficacy of lurbinectedin in SCLC and other tumors. The drug’s activity in this disease and setting has been reinforced in this trial,” said Luis Mora<\/span>, managing director, oncology business unit, PharmaMar. “We extend our gratitude to the patients, physicians and their staff as well as caregivers who participated in this clinical study.”<\/p>\n

“Historically, patients with relapsed SCLC often face difficult odds due to the aggressive nature of the disease and they have had very limited treatment options. As a physician treating patients with SCLC, I’m confident in lurbinectedin\u00a0as an effective new option in this traditionally challenging therapeutic area,” Alberto Chiappori<\/span>, MD, senior member of oncology and medicine for the Department of Thoracic Oncology at the H. Lee Moffitt Cancer Center and Research Institute and ATLANTIS Phase 3 study investigator.<\/p>\n

Results will be discussed with the appropriate regulatory authorities and will be presented at a future medical meeting. <\/p>\n

The U.S. Food and Drug Administration (FDA) approved Zepzelca <\/i>under accelerated approval in June 2020<\/span> for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy. The approval is based on ORR and duration of response demonstrated in an open-label, monotherapy clinical study. The companies will provide the ATLANTIS data to FDA and look forward to working with the agency to determine the confirmatory data that is needed for full approval.<\/p>\n

\n ATLANTIS Phase 3 Study Design
<\/b>The ATLANTIS Phase 3 study enrolled 613 patients at 154 sites primarily in the U.S., Canada<\/span>, Latin America<\/span> and Western Europe<\/span> from September 2016<\/span> through July 2018<\/span>. Patients enrolled were \u226518 years with histologically or cytologically confirmed diagnosis of limited or extensive stage SCLC, had failed one prior platinum-containing regimen, and had a chemotherapy-free interval (CTFI, time from the last dose of first-line chemotherapy to the occurrence of progressive disease) \u2265 30 days. Patient inclusion criteria included small-cell carcinoma of unknown primary site with or without neuroendocrine features confirmed in histology test(s) performed on metastatic lesion(s) are eligible, if Ki-67\/MIB-1 is expressed in >50 percent of tumor cells.<\/p>\n

In the trial, patients were randomized in a 1:1 ratio to receive lurbinectedin in combination with doxorubicin or physician’s choice of topotecan OR cyclophosphamide\/doxor ubicin\/vincristine (CAV). The primary endpoint was overall survival. The secondary endpoints were 1) the difference in OS for patients in the\u00a0lurbinectedin\/doxorubicin arm compared to patients treated with CAV; 2) OS and progression free survival (PFS) in patients with or without CNS involvement; 3) PFS by independent review committee (IRC); 4) antitumor activity defined by objective response rate (ORR) per IRC; and 5) duration of response per IRC. <\/p>\n

The study sample was stratified by the following factors: CTFI (chemotherapy free interval); ECOG performance status (0 vs. 1-2); CNS involvement vs. no involvement; prior immunotherapy against either programmed cell death protein-1 (PD-1) or programmed death ligand-1 (PD-L1); and investigator preference of topotecan and CAV.<\/p>\n

\n About\u00a0Zepzelca\u2122\u00a0<\/i>(lurbinectedin)<\/b>
\n
\n Zepzelca<\/i> is an alkylating drug that binds guanine residues within DNA. This triggers a cascade of events that can affect the activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in disruption of the cell cycle and eventual cell death.1<\/sup><\/p>\n

\n Zepzelca<\/i>\u00a0for injection 4 mg is a prescription medicine used to treat adults with a kind of lung cancer called small cell lung cancer that has spread to other parts of the body (metastatic) and who have received treatment with chemotherapy that contains platinum, and it did not work or is no longer working.\u00a0Zepzelca<\/i>\u00a0is approved based on response rate and how long the response lasted. Additional studies will further evaluate the benefit of\u00a0Zepzelca<\/i>\u00a0for this use.<\/p>\n

\n Important Safety Information<\/b>\n <\/p>\n

\n Before receiving ZEPZELCA, tell your healthcare provider about all of your medical conditions, including if you:<\/b>\n <\/p>\n